The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • ECS Botanics (ECS) has been granted an Industrial Hemp Special Research Licence for its Tasmanian farm
  • This new licence enables ECS to work with up to two per cent dry weight of THC versus the standard one per cent limit
  • The company can also grow up to 100 plants at any one time and hold a maximum of one kilogram of hemp seeds
  • This licence is valid until April 2023
  • ECS has closed the day 4.76 per cent in the green with shares trading for 2.2 cents each

ECS Botanics (ECS) has been granted an Industrial Hemp Special Research Licence for its Tasmanian farm.

This new licence is issued under section 14 of the Tasmanian Industrial Hemp Act 2015. The Act reads “A special licence may authorise a person to possess, cultivate or supply hemp, that is not industrial hemp, for the purpose of scientific research, instruction, analysis or study.”

The new licence is different to the research licence that ECS currently holds, allowing the company to work with up to two per cent w/w (weight for weight) dry weight of delta-9-tetrehydrocannabinol (THC) versus the standard one per cent limit.

ECS is now able to cultivate, manufacture and supply hemp that has a concentration of up to two per cent THC for scientific research, analysis and study.

Additionally, ECS can grow up to 100 plants at any one time and hold a maximum of one kilogram of hemp seeds.

This licence is valid from March 6 2020 to April 3 2023.

“The granting of the special research licence affords ECS more flexibility in research programs,” Managing Director Alex Keach commented.

“Along with our strategy of being the first mover in the evolving hemp industry, this licence will enable us to trial, develop and test genetics with respect to cultivation methods, cannabinoid expression and more,” he added.

ECS has closed the day 4.76 per cent in the green with shares trading for 2.2 cents each in a $10.65 million market cap.

ECS by the numbers
More From The Market Online

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Brian Leedman’s BlinkLab to join ASX: AI-driven smartphone app screens for autism, ADHD

BlinkLab is a world-first, AI-driven digital healthcare venture, that uses a smartphone and facial recognition to…

Osteopore stock spikes 900% on Singapore and Vietnam approvals

Osteopore's (ASX:OSX) share price was up 38% after the regenerative medicine company received approval for its…

Amplia Therapeutics takes step up in pancreatic cancer treatment

Amplia Therapeutics is on to next step in its pancreatic cancer treatment research after a successful…